TY - JOUR
T1 - A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis
AU - Ho, Ken K.Y.
AU - Fleseriu, Maria
AU - Wass, John
AU - Katznelson, Laurence
AU - Raverot, Gerald
AU - Little, Andrew S.
AU - Castaño, Justo P.
AU - Reincke, Martin
AU - Lopes, M. Beatriz
AU - Kaiser, Ursula B.
AU - Chanson, Philippe
AU - Gadelha, Mônica
AU - Melmed, Shlomo
N1 - Publisher Copyright:
© 2024 Elsevier Ltd
PY - 2024/3
Y1 - 2024/3
N2 - No comprehensive classification system that guides prognosis and therapy of pituitary adenomas exists. The 2022 WHO histopathology-based classification system can only be applied to lesions that are resected, which represent few clinically significant pituitary adenomas. Many factors independent of histopathology provide mechanistic insight into causation and influence prognosis and treatment of pituitary adenomas. We propose a new approach to guide prognosis and therapy of pituitary adenomas by integrating clinical, genetic, biochemical, radiological, pathological, and molecular information for all adenomas arising from anterior pituitary cell lineages. The system uses an evidence-based scoring of risk factors to yield a cumulative score that reflects disease severity and can be used at the bedside to guide pituitary adenoma management. Once validated in prospective studies, this simple manageable classification system could provide a standardised platform for assessing disease severity, prognosis, and effects of therapy on pituitary adenomas.
AB - No comprehensive classification system that guides prognosis and therapy of pituitary adenomas exists. The 2022 WHO histopathology-based classification system can only be applied to lesions that are resected, which represent few clinically significant pituitary adenomas. Many factors independent of histopathology provide mechanistic insight into causation and influence prognosis and treatment of pituitary adenomas. We propose a new approach to guide prognosis and therapy of pituitary adenomas by integrating clinical, genetic, biochemical, radiological, pathological, and molecular information for all adenomas arising from anterior pituitary cell lineages. The system uses an evidence-based scoring of risk factors to yield a cumulative score that reflects disease severity and can be used at the bedside to guide pituitary adenoma management. Once validated in prospective studies, this simple manageable classification system could provide a standardised platform for assessing disease severity, prognosis, and effects of therapy on pituitary adenomas.
UR - http://www.scopus.com/inward/record.url?scp=85184166921&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85184166921&partnerID=8YFLogxK
U2 - 10.1016/S2213-8587(23)00382-0
DO - 10.1016/S2213-8587(23)00382-0
M3 - Review article
C2 - 38301678
AN - SCOPUS:85184166921
SN - 2213-8587
VL - 12
SP - 209
EP - 214
JO - The Lancet Diabetes and Endocrinology
JF - The Lancet Diabetes and Endocrinology
IS - 3
ER -